High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection.
Perihilar cholangiocarcinoma
Prognostic factor
Tumor budding
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
received:
15
01
2020
accepted:
28
02
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Tumor budding (TB) is used as an indicator of poor prognosis in various cancers. However, studies on TB in perihilar cholangiocarcinoma are still limited. We examined the significance of TB in resected perihilar cholangiocarcinoma with or without neoadjuvant therapy. Seventy-eight patients who underwent surgical resection at our institution for perihilar cholangiocarcinoma from 2004 to 2017, (36 with neoadjuvant therapy), were enrolled in this study. TB was defined as an isolated cancer cell or clusters (< 5 cells) at the invasive front and the number of TB was counted using a 20 times objective lens. Patients were classified into two groups according to TB counts: low TB (TB < 5) and high TB (TB ≥5). In this 78 patient cohort, high TB was significantly associated with advanced tumor status (pT4: 50.0% vs 22.2%, p = 0.007, pN1/2: 70.8% vs 39.6%, p = 0.011, M1: 20.8% vs 1.9%) and higher histological grade (G3: 25.0% vs 5.7%, p = 0.014). Disease specific survival (DSS) in high TB was significantly inferior compared to that in low TB group (3-y DSS 14.5% vs 67.7%, p < 0.001). Interestingly, DSS in high TB showed similar to survival in unresected patients. In addition, high TB was also associated with advanced tumor status and poor prognosis in patients with neoadjuvant therapy. Multivariate analysis identified high TB as an independent poor prognostic factors for DSS (HR: 5.206, p = 0.001). This study demonstrated that high TB was strongly associated with advanced tumor status and poor prognosis in resected perihilar cholangiocarcinoma patients. High TB can be a novel poor prognostic factor in resected perihilar cholangiocarcinoma regardless of neoadjuvant therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor budding (TB) is used as an indicator of poor prognosis in various cancers. However, studies on TB in perihilar cholangiocarcinoma are still limited. We examined the significance of TB in resected perihilar cholangiocarcinoma with or without neoadjuvant therapy.
METHODS
METHODS
Seventy-eight patients who underwent surgical resection at our institution for perihilar cholangiocarcinoma from 2004 to 2017, (36 with neoadjuvant therapy), were enrolled in this study. TB was defined as an isolated cancer cell or clusters (< 5 cells) at the invasive front and the number of TB was counted using a 20 times objective lens. Patients were classified into two groups according to TB counts: low TB (TB < 5) and high TB (TB ≥5).
RESULTS
RESULTS
In this 78 patient cohort, high TB was significantly associated with advanced tumor status (pT4: 50.0% vs 22.2%, p = 0.007, pN1/2: 70.8% vs 39.6%, p = 0.011, M1: 20.8% vs 1.9%) and higher histological grade (G3: 25.0% vs 5.7%, p = 0.014). Disease specific survival (DSS) in high TB was significantly inferior compared to that in low TB group (3-y DSS 14.5% vs 67.7%, p < 0.001). Interestingly, DSS in high TB showed similar to survival in unresected patients. In addition, high TB was also associated with advanced tumor status and poor prognosis in patients with neoadjuvant therapy. Multivariate analysis identified high TB as an independent poor prognostic factors for DSS (HR: 5.206, p = 0.001).
CONCLUSION
CONCLUSIONS
This study demonstrated that high TB was strongly associated with advanced tumor status and poor prognosis in resected perihilar cholangiocarcinoma patients. High TB can be a novel poor prognostic factor in resected perihilar cholangiocarcinoma regardless of neoadjuvant therapy.
Identifiants
pubmed: 32164621
doi: 10.1186/s12885-020-6695-9
pii: 10.1186/s12885-020-6695-9
pmc: PMC7069056
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209Références
Cancer. 2009 Jul 15;115(14):3324-34
pubmed: 19452547
Cancer Sci. 2013 Sep;104(9):1211-6
pubmed: 23763511
Hepatol Res. 2014 Oct;44(10):E118-28
pubmed: 24397273
Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9
pubmed: 23355041
Surgery. 2018 Apr;163(4):732-738
pubmed: 29336813
J Gastrointest Surg. 2017 Mar;21(3):590-599
pubmed: 27896655
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
J Gastrointest Surg. 2010 Feb;14(2):335-43
pubmed: 19902311
Hum Pathol. 2012 Jul;43(7):1061-7
pubmed: 22204710
Hum Pathol. 2010 Aug;41(8):1061-8
pubmed: 20413143
Histopathology. 2019 May;74(6):861-872
pubmed: 30667537
J Am Coll Surg. 2015 Dec;221(6):1041-9
pubmed: 26454735
Ann Surg. 2013 Jul;258(1):129-40
pubmed: 23059502
Histopathology. 2014 Nov;65(5):623-30
pubmed: 24701980
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Eur J Cancer. 2013 Mar;49(5):1032-9
pubmed: 23177090
Am J Surg Pathol. 2010 Oct;34(10):1417-24
pubmed: 20871215
Mod Pathol. 2013 Feb;26(2):295-301
pubmed: 23018875
J Surg Oncol. 2018 May;117(6):1278-1287
pubmed: 29572828
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
World J Surg. 2018 Sep;42(9):2910-2918
pubmed: 29511872
Nat Genet. 2007 Apr;39(4):467-75
pubmed: 17369830
Am J Surg Pathol. 2019 Sep;43(9):1180-1190
pubmed: 31335353
Br J Surg. 2010 Jan;97(1):56-64
pubmed: 19937985
HPB (Oxford). 2014 Apr;16(4):297-303
pubmed: 23981000
Virchows Arch. 2011 Oct;459(4):449-56
pubmed: 21785869